Literature DB >> 11830441

Home sequential high dose intravenous immunoglobulins in systemic autoimmune disease.

E Hachulla, A Wibaux, P Y Hatron, U Michon-Pasturel, V Queyrel, A L Fauchais, B Devulder, M N Lefebvre, M Yilmaz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11830441      PMCID： PMC1754022          DOI： 10.1136/ard.61.3.277-a

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  3 in total

1.  Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study.

Authors:  Eric Hachulla; Gwendal Le Masson; Guilhem Solé; Mohamed Hamidou; Claude Desnuelle; Jean-Philippe Azulay; Gérard Besson; Laure Swiader; Sébastien Abad; Jean-Christophe Antoine; Françoise Bouhour; Alain Créange; Marike Grenouillet; Laurent Magy; Sébastien Marcel; Jean-Michel Paquet; François Rouhart; François Ziegler; Stéphane Mathis; Marc Gauthier-Darnis; Sophie Puget
Journal:  Biomed Res Int       Date:  2018-03-15       Impact factor: 3.411

2.  Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".

Authors:  B Bienvenu; G Cozon; C Hoarau; M Pasquet; P Cherin; P Clerson; E Hachulla; J C Crave; J C Delain; R Jaussaud
Journal:  Orphanet J Rare Dis       Date:  2016-06-22       Impact factor: 4.123

3.  Home versus hospital immunoglobulin treatment for autoimmune neuropathies: A cost minimization analysis.

Authors:  Gwendal Le Masson; Guilhem Solé; Claude Desnuelle; Emilien Delmont; Marc Gauthier-Darnis; Sophie Puget; Isabelle Durand-Zaleski
Journal:  Brain Behav       Date:  2018-01-26       Impact factor: 2.708
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.